Deciphera Pharmaceuticals, Inc.
Thesis
Deciphera Pharmaceuticals has a promising pipeline of cancer therapies that could lead to significant revenue growth in the coming years. The company's focus on targeted therapies positions it well in the competitive oncology market.
Did it work?
The pitch is a generic long thesis premised on pipeline-driven revenue growth, but no price performance, no stated horizon, and no pitch date are provided, making it impossible to weigh the return against the thesis direction. While Deciphera did achieve regulatory milestones (e.g., QINLOCK's FDA approval) and was ultimately acquired by Ono Pharmaceutical at a premium, without knowing when the pitch was made or the entry price, these events cannot be reliably attributed to the thesis playing out. The absence of both price data and a defined timeline leaves the verdict undetermined.